Biotech Startups Get a Boost: ZAGENO and Hatch.Bio Labs Partner to Streamline Lab Operations
8.1.2025 09:30:00 CET | ACCESS Newswire | Press release
ZAGENO Forms a Strategic Partnership With Hatch.Bio Labs, a Premier Biotech Incubator
BOSTON, MA / ACCESSWIRE / January 8, 2025 / Biotech startups often encounter administrative roadblocks on their path to achieving breakthroughs in life sciences. Today, ZAGENO, the leading AI-powered marketplace for lab supplies, and Hatch.Bio Labs, a premier biotech incubator, join forces to eliminate these challenges.ZAGENO x Hatch.Bio Labs
ZAGENO and Hatch.Bio Labs Partner to Streamline Lab Operations
This strategic partnership empowers Hatch.Bio residents with a streamlined lab supply procurement process, allowing them to prioritize groundbreaking research. ZAGENO's platform offers an Amazon-like shopping experience for lab supplies, featuring:
Effortless Management: Discounted rates, easy price comparison of 5,300+ suppliers, single bill-to options, and automated order tracking.
Dedicated Support: Fast onboarding, procurement best practices, and frequent on-site guidance to maximize platform value.
Reduced Costs: Exclusive discounts for Hatch members, with free access for smaller startups.
"Biotech startups are at the forefront of innovation, but administrative hurdles can delay their progress," says Florian Wegener, CEO and Founder of ZAGENO. "Our partnership with Hatch.Bio simplifies lab supply ordering for their members, saving them valuable time and resources."
James Weis, Hatch.Bio CEO, adds, "This collaboration provides our residents with a critical operational advantage, allowing them to streamline operations and accelerate research."
Through this partnership, Hatch.Bio tenants will gain seamless access to ZAGENO's AI-powered lab supply marketplace. By integrating ZAGENO's platform with Hatch.Bio's facilities and support, this collaboration simplifies procurement, automates tracking, and minimizes administrative tasks, freeing researchers to focus on advancing their research to the clinic.
About ZAGENO
ZAGENO is transforming lab supply procurement with the industry's largest AI-powered marketplace, featuring over 40 million products from 5,300+ global suppliers. Scientists, lab managers, and procurement teams rely on ZAGENO's all-in-one platform for painless lab supply procurement that optimizes budgets and enhances productivity. With automated order and delivery tracking, custom workflows, real-time spend analytics, and offloaded supplier management, ZAGENO empowers labs of all sizes to achieve full lab supply ordering automation. Explore ZAGENO's marketplace and discover how it can streamline your lab supply procurement: www.zageno.com or request access at bit.ly/HatchBio-Labs.
About Hatch.Bio Labs
Hatch.Bio Labs is the premier biotechnology and life sciences incubation platform dedicated to reducing operational barriers for biotechnology and life sciences companies. We provide best-in-class, highly flexible, and cost-effective laboratory and office facilities, natively integrated with comprehensive scientific and operational support and strategic partnerships within a modern technology stack-all to help our resident companies grow more rapidly and efficiently. Our mission is to empower biotech pioneers to develop transformative technologies and advance the pace of biotechnology innovation. For more information and to inquire about becoming a tenant, visit www.hatch.bio.
Contact Information
Stephanie Harold
pr@zageno.com
+1 (857) 477-8479
SOURCE: ZAGENO
View the original press release on accesswire.com
ZAGENO
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom